Sun Chang Kim

This inventor holds 17 USPTO granted patents and 6 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Composition. Top assignees: Intelligent Synthetic Biology Center, Korea Advanced Institute of Science and Technology, Korea Research Institute of Bioscience and Biotechnology. Active years: 2001-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sun Chang Kim. Retrieved from https://idiyas.com/inventor/sun-chang-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 47.1

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 18)

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Taejon, KR (2001)
Daejeon, KR (2011 - 2020)

Company Filing History:

11 out of 20

Intelligent Synthetic Biology Center

patents

6 out of 2,803

Korea Advanced Institute of Science and Technology

patents

1 out of 336

Korea Research Institute of Bioscience and Biotechnology

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

Areas of Expertise:

Ginsenoside F1

Vascular Leak Syndrome

Cervical Cancer

Leukemia Treatment

Amyloid Plaques

Ginsenoside Glycosylation

Liver Cancer

Protein-Protein Interaction

Anticancer Agents

VEGF-A Binding

Amino Acid Biosynthesis

Antimicrobial Peptides

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10682366 - Method for enhancing immunity using ginsenoside F1 as an active ingredient (2020-06-16),

2. 10391111 - Composition for preventing or treating cervical cancer including gypenoside LXXV (2019-08-27),

3. 10391110 - Composition for preventing or treating vascular leak syndrome (2019-08-27),

4. 10376530 - Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside R3 as an active ingredient (2019-08-13),

5. 10330672 - Method for screening activator of mitochondrial activity (2019-06-25),

6. 10307436 - Composition containing ginsenoside F1 for removing amyloid plaques (2019-06-04),

7. 10301654 - Method of preparing cinnamaldehyde (2019-05-28),

8. 10174355 - Method for glycosylation of ginsenoside using a glycosyltransferase derived from panax ginseng (2019-01-08),

9. 9943534 - Composition for preventing or treating liver cancer containing ginsenoside F2 (2018-04-17),

10. 9926585 - Method for producing a minor ginsenoside using a ginsenoside glycosidase (2018-03-27),

11. 9784747 - Method and kit for analyzing protein-protein interaction using nanocluster formation (2017-10-10),

12. 9067970 - Anticancer agents comprising peptides with cancer-specific toxicity (2015-06-30),

13. 8927232 - Fusion protein capable of binding VEGF-A and TNF-alpha (2015-01-06),

14. 8735129 - [object Object] (2014-05-27),

15. 8367380 - Compositions and methods for amino acid biosynthesis (2013-02-05),

Title: Sun Chang Kim: Innovator in Immunity Enhancement and Vascular Health

Introduction

Sun Chang Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in enhancing immunity and addressing vascular health issues. With a total of 17 patents to his name, Kim's work is recognized for its innovative approaches and practical applications.

Latest Patents

Among his latest patents, Kim has developed a method for enhancing immunity using ginsenoside F1 as an active ingredient. This invention relates to compositions that promote innate immunity by enhancing the degranulation activity and cell-killing activity of natural killer cells. The composition effectively increases the expression of cell-killing factors, making it a valuable tool for boosting innate immunity. Another notable patent is a composition for preventing or treating vascular leak syndrome. This pharmaceutical composition, which contains ginsenoside F1 or Rh1, is designed to prevent or treat vascular leak syndrome. It promotes angiogenesis and suppresses vascular leakage, thus offering a promising solution for managing this condition.

Career Highlights

Sun Chang Kim has worked with esteemed institutions such as the Intelligent Synthetic Biology Center and the Korea Advanced Institute of Science and Technology. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Wan Taek Im and Chang Hao Cui. Their collaborative efforts have further advanced the research and development of innovative solutions in biotechnology.

Conclusion

Sun Chang Kim's contributions to the fields of immunity enhancement and vascular health through his patents demonstrate his commitment to innovation and scientific advancement. His work continues to impact the biotechnology landscape positively.

Profile summary based on public USPTO records.